The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
Investment will support discovery research of a novel Gene CodingTM approach that could benefit all people with CF regardless of their mutation
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
The treatment has the potential to prevent Aspergillus fungal infections in people who have had a lung transplant.
Foundation to fund up to $110 million for collaboration to accelerate the development of genetic therapies for CF
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
New funding will support clinical development of two novel therapies to address complications of cystic fibrosis
The Cystic Fibrosis Registry Global Harmonization Group, including the Cystic Fibrosis Foundation, published findings from the first global study on the impact of COVID-19 on children with cystic fibrosis in the Journal of Cystic Fibrosis.